Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Disease

journal homepage: www.elsevier.com/locate/apjtd



Document heading doi: 10.1016/S2222-1808(13)60094-8

Basic and modern concepts on cholinergic receptor: A review

Prashant Tiwari[1*], Shubhangi Dwivedi[1], Mukesh Pratap Singh[1], Rahul Mishra[2], Anish Chandy[1]

[1]*School of Pharmacy, Chouksey Engineering College, Bilaspur-495004 India*

[2]*Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra Ranchi-835215, India*

PEER REVIEW

Peer reviewer

Rakesh Tirkey, Assistant Professor, University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, 492010 India.
Tel: 09752518572
Fax: 0771 226 2857
E-mail: rakeshtirkey99@gmail.com

Comments

This article serves as both structural and functional source of information regarding cholinergic receptors and provides a detailed understanding of the determinants governing specificity of muscarinic and nicotinic receptor to researchers.
Details on Page 418

ABSTRACT

Cholinergic system is an important system and a branch of the autonomic nervous system which plays an important role in memory, digestion, control of heart beat, blood pressure, movement and many other functions. This article serves as both structural and functional sources of information regarding cholinergic receptors and provides a detailed understanding of the determinants governing specificity of muscarinic and nicotinic receptor to researchers. The study helps to give overall information about the fundamentals of the cholinergic system, its receptors and ongoing research in this field.

KEYWORDS

Cholinergic system, Peripheral nervous system, Muscarinic, Nicotinic receptors

1. Introduction

The autonomic nervous system (ANS or visceral nervous system) is the part of the peripheral that acts as a control system functioning largely below the level of consciousness, and controls visceral functions. The ANS affects heart rate, digestion, respiration rate, salivation, perspiration, dilation of the pupils, micturition (urination), and sexual arousal. It is classically divided into two subsystems: the parasympathetic nervous system (PSNS) and sympathetic nervous system (SNS). Recently, a third subsystem of neurons that have been named non-adrenergic and non-cholinergic neurons (because they use nitric oxide as a neurotransmitter) have been described and found to be integral in autonomic function, particularly in the gut and the lungs. ANS innervation is divided into SNS and PSNS divisions. The sympathetic division has thoracolumbar outflow, meaning that the neurons begin at the thoracic and lumbar (T1-L2) portions of the spinal cord. The parasympathetic division has craniosacral outflow, meaning that the neurons begin at the cranial nerves (CN 3, CN 7, CN 9, CN 10) and sacral (S2-S4) spinal cord. The ANS is unique in that it requires a sequential two-neuron efferent pathway; the preganglionic neuron must first synapse onto a postganglionic neuron before innervating the target organ. The preganglionic, or first, neuron will begin at the outflow and will synapse at the postganglionic, or second, neuron's cell body. The post ganglionic neuron will then synapse at the target organ.

*Corresponding author: School of Pharmacy, Chouksey Engineering College, Bilaspur-495004 India.
Tel: +91-7828865022
Fax: 07753-302101
E-mail: ptc_ptc15@rediffmail.com
Foundation Project: Financially supported by Chhattisgarh Council Of Science & Technology (CGCOST) (Grant No. 146/CCOST/2008).

Article history:
Received 25 Jul 2013
Received in revised form 29 Jul, 2nd revised form 4 Aug, 3rd revised form 12 Aug 2013
Accepted 5 Sep 2013
Available online 28 Oct 2013

2. Sympathetic division

The sympathetic division (thoracolumbar outflow) consists of cell bodies in the lateral horn of spinal cord (intermediolateral cell columns) of the spinal cord from T1 to L2. These cell bodies are general visceral efferent (GVE) neurons and are the preganglionic neurons. There are several locations upon which preganglionic neurons can synapse for their postganglionic neurons:

▷ Paravertebral ganglia of the sympathetic chain (these run on either side of the vertebral bodies).

▷ Prevertebral ganglia (celiac ganglia, superior mesenteric ganglia, and inferior mesenteric ganglia).

▷ Chromaffin cells of adrenal medulla (this is the one exception to the two-neuron pathway rule: synapse is direct onto the target cell bodies).

These ganglia provide the postganglionic neurons from which innervation of target organs follows. Examples of splanchnic (visceral) nerves are:

▷ Cervical cardiac nerves and thoracic visceral nerves which synapse in the sympathetic chain.

▷ Thoracic splanchnic nerves (greater, lesser, least) which synapse in the prevertebral ganglion.

▷ Lumbar splanchnic nerves which synapse in the prevertebral ganglion.

▷ Sacral splanchnic nerves which synapse in the inferior hypogastric plexus.

These all contain afferent (sensory) nerves as well, known as GVA (general visceral afferent) neurons.

3. Parasympathetic division

The parasympathetic division (craniosacral outflow) consists of cell bodies from one of two locations: brainstem (cranial nerves III, VII, IX, X) or sacral spinal cord (S2, S3, S4). These are the preganglionic neurons, which synapse with postganglionic neurons in these locations:

▷ Parasympathetic ganglia of the head [ciliary (CN III), submandibular (CN VII), pterygopalatine (CN VII), and otic (CN IX)].

▷ In or near wall of organ innervated by vagus (CN X), sacral nerves (S2, S3, S4).

These ganglia provide the postganglionic neurons from which innervations of target organs follows. Examples are:

▷ The preganglionic parasympathetic splanchnic (visceral) nerves.

▷ Vagus nerve, which wanders through the thorax and abdominal regions innervating, among other organs, the heart, lungs, liver and stomach.

4. Cholinergic receptors

The term cholinergic refers to those receptors which respond to the transmitter acetylcholine and are mostly parasympathetic. There are two types of cholinergic receptors, classified according to whether they are stimulated by the drug nicotine or by the drug muscarine.

4.1. Muscarinic receptors

Muscarinic receptors are found at parasympathetic target organs and at certain sympathetic targets – the eccrine sweat glands (which produces copious secretion in thermoregulation to release heat), and blood vessels in skeletal muscles (which are dilated). Muscarinic acetylcholine receptors in the peripheral nervous system are found primarily on autonomic effector cells innervated by postganglionic parasympathetic nerves. Muscarinic receptors are also present in ganglia and on some cells, such as endothelial cells of blood vessels that receive little or no cholinergic innervation. Within the central nervous system (CNS), the hippocampus, cortex, and thalamus have high densities of muscarinic receptors. Muscarinic receptors were characterized initially by analysis of the responses of cells and tissues in the periphery and the CNS. Differential effects of two muscarinic agonists, bethanechol and McN-A-343, on the tone of the lower esophageal sphincter led to the initial designation of muscarinic receptors as M_1 (ganglionic) and M_2 (effector cell). The basis for the selectivity of these agonists is unclear, as there is limited evidence that agonists discriminate appreciably among the subtypes of muscarinic receptors[1,2]. However, subsequent radioligand binding studies definitively revealed distinct populations of antagonist binding sites[3].

In particular, one region at the carboxyl-terminal end of the third intracellular loop of the receptor has been implicated in the specificity of G protein coupling and shows extensive homology within M_1, M_3, and M_5 receptors and between M_2 and M_4 receptors. Conserved regions in the second intracellular loop also confer specificity for proper G protein recognition. Although selectivity is not absolute, stimulation of M_1 or M_3 receptors causes hydrolysis of polyphosphoinositides and mobilization of intracellular Ca^{2+} as a consequence of activation of the G_q-PLC pathway; this effect in turn results in a variety of Ca^{2+}-mediated events, either directly or as a consequence of the phosphorylation of target proteins. In contrast, M_2 and M_4 muscarinic receptors inhibit adenylyl cyclase and regulate specific ion channels (*e.g.*, enhancement of K^+ conductance in cardiac atrial tissue) through subunits released from pertussis toxin-sensitive G proteins (G_i and G_0) that are distinct from the G proteins used by M_1 and M_3 receptors[4]. In particular, the muscarinic antagonist pirenzepine was shown to bind with high affinity to sites in cerebral cortex and sympathetic ganglia (M_1) but to have lower affinity for sites in cardiac muscle, smooth muscle, and various glands. These data explain the ability of pirenzepine to block agonist-induced responses that are mediated by muscarinic receptors in sympathetic and

myenteric ganglia at concentrations considerably lower than those required to block responses that result from direct stimulation of receptors in various effector organs. Antagonists that can further discriminate among various subtypes of muscarinic receptors are now available. For example, tripitramine displays selectivity for cardiac M_2 relative to M_3 muscarinic receptors, while darifenacin is relatively selective for antagonizing glandular and smooth muscle M_3 relative to M_2 receptors[5].

The cloning of the cDNAs that encode muscarinic receptors identified five distinct gene products now designated as M_1 through M_5. All of the known muscarinic receptor subtypes interact with members of a group of heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) that in turn are linked to various cellular effectors. Regions within the receptor responsible for the specificity of G protein coupling have been defined primarily by receptor mutants and chimeras formed between receptor subtypes.

We also find the muscarinic receptors bind acetylcholine to transduce signals in the central nervous system, autonomic ganglia, smooth muscles, and parasympathetic organs. The five closely related receptor subtypes (M_1-M_5) are members of the class A (rhodopsin-like) superfamily of G-protein-coupled receptors. Nathanson tells that muscarinic acetylcholine receptors are members of the G-protein coupled receptor superfamily which are expressed in and regulate the function of neurons, cardiac and smooth muscle, glands, and many other cell types and tissues. These receptors possess seven membrane-spanning domains and specific sites for glycosylation, phosphorylation, lipid modification, and interaction with heterotrimeric transducer G-proteins. M_1, M_3, and M_5 receptors are efficiently coupled through $G_{q/11}$ proteins to phospholipase Cβ, producing the second messengers diacylglycerol and inositol triphosphate[6]. Although we have an recent update about the type and its role in a large number of physiological processes, such as the function of heart and smooth muscles, glandular secretion, release of neurotransmitters, gene expression and cognitive functions as learning and memory[7]. However, contraction of the guinea-pig isolated gallbladder mediating muscarinic receptor which belongs to the M_3 or M_4 subtype and which was characterized by subtype agonists and antagonists[8].

The researchers also investigated the subtype of prejunctional muscarinic receptors which is associated with inhibition of acetylcholine (ACh) released from the mouse bladder and was measured endogenous ACh release in the bladder that was obtained from the wild-type mice and muscarinic 1-5 (M_1-M_5) receptor knockout (KO) mice[9], and properties of ligand binding presynaptic muscarinic receptors present in purified synaptosomal fraction isolated from the electric organ of *Torpedo*. They studied the above phenomena by the specific tritiated antagonist N-methyl-4-piperidylbenzilate ([^{3}H]-4NMPB), direct and competition binding studies of antagonists with high affinity to the presynaptic receptor, and saturability occurring at very low ligand concentration, in a stereospecific manner as well as simple mass action law[10], and some study also derived five subtypes of muscarinic acetylcholine receptors (M_1 to M_5) which control physiological processes, such as the function of heart and smooth muscles, glandular secretion, release of neurotransmitters, gene expression and cognitive functions as learning and memory helps us to understand the subtypes of the muscarinic acetylcholine receptors, the role in physiological processes and role in different processes. AFRC Laboratory of Molecular Signalling, Department of Zoology, University of Cambridge studied the role of muscarinic acetylcholine receptors (mAChRs) on the cell body of the fast coxal depressor motor neurone (D_f) in the metathoracic ganglion of the cockroach *Periplaneta*, investigated using electrophysiological methods[11].

However, the analysis of muscarinic receptor concentration and subtypes following lesion of rat substantia innominata and that cholinergic neurones located in the nucleus basalis of Meynert (NBM) in the substantia innominata (SI) which is known to project to cerebral cortex and cell loss in NBM was associated with the cholinergic deficit seen in Alzheimer's disease. There was examined effect of lesion of SI with kainate (1 μg/0.5 μL) on acetylcholine esterase (AChE) activity, muscarinic receptor number and subtypes in cerebral cortex at 1, 2 and 4 weeks[12], and M_1- and M_2-receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens and concluded that twitch contractions of the rabbit vas deferens elicited field stimulation was inhibited by tetrodotoxin, guanethidine, bretylium and α, β-methylene-ATP, but that was unaffected by hexamethonium, physostigmine, 1,1-dimethyl-4-phenylpiperazinium and prazosin, therefore they resulted from ATP released postganglionic sympathetic nerve stimulation. Studies have been also regarding the agents which either act as agonist to the muscarinic receptors or antagonize its action[13]. Freschi finds that muscarinic agonists evoke a voltage dependent inward current in motoneurons of the lobster cardiac ganglion, and a number of drugs known to show muscarinic receptor subtype selectivity in mammals were used to determine the pharmacological profile of the muscarinic receptor on lobster motoneurons[14]. Some of the differential regulation of muscarinic and nicotinic receptors by cholinergic stimulation in cultured avian retina cells concludes that sustained cholinergic stimulation of retina cells grown in primary aggregate and monolayer cultures regulated the concentration of muscarinic, but not regulated nicotinic receptors. Muscarinic receptor sites, binding of the [^{3}H] quinuclidinyl benzilate to membranes and the binding of [^{3}H] N-methyl-scopolamine to intact cells, decreased up to 84% following long-term incubation of cultures in muscarinic agonists[15].

It has also found that the G-protein-coupled receptors regulate membrane excitability via M-type K^+ current (M-current) modulation. Muscarinic M_1 and M_3 acetylcholine

receptors have both been implicated in the modulation of M-current. The muscarinic M_5 receptor, like muscarinic M_1 and M_3 receptors, couples to phospholipase C via a pertussis toxin-insensitive G protein[16]. We also investigate potential benefits of muscarinic M_3 receptor selectivity, and it conclude that smooth muscle contains muscarinic receptors of the M_2 (≈2/3) and M_3 (≈1/3) subtypes. M_3 receptors are mainly responsible for normal micturition contraction, whereas, the role of M_2 receptors has not still been clarified. In certain disease states, M_2 receptors may also contribute to bladder contraction[17].

The role of M_2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M_3 inactivation and finds that bladder body M_2 muscarinic receptors predominate but a smaller population of M_3 receptors mediates direct contraction. M_2 receptors has indirect role by inhibiting cyclic adenosine monophosphate mediated relaxation in the bladder body[18], and it has also investigated the influence of two toxins from the black mamba *Dendroaspis polylepis* on the kinetics of [^{3}H]-N-methylscopolamine binding to muscarinic acetylcholine receptors from rat cerebral cortex and it was revealed that these toxins, MTα and MTβ, interact with the receptors via kinetically distinct mechanisms[19]. Kimber studied the structure, pharmacology and physiological importance of LGICs in model nematodes, including parasitic species where they are targets for anthelmintic drugs[20], and we have also investigated the ability of the M_2/M_4 muscarinic ACh receptor antagonist N, N′-bis [6-[[(2-methoxyphenyl) methyl] amino] hexyl]-1, 8-octane diamine tetrahydrochloride (methoctramine) to induce and modulate synaptic plasticity in the CA1 area of the hippocampus in urethane-anesthetized rats[21].

4.2. Nicotinic receptors

The nicotinic acetylcholine (ACh) receptor mediates neurotransmission postsynaptically at the neuromuscular junction and peripheral autonomic ganglia; in the CNS, it largely controls release of neurotransmitters from presynaptic sites. Distinct subtypes of nicotinic receptors exist at the neuromuscular junction and the ganglia, and several pharmacological agents that act at these receptors discriminate between them. Classical studies of the actions of curare and nicotine made this the prototypical pharmacological receptor over a century ago. By taking advantage of specialized structures that have evolved to mediate cholinergic neurotransmission and natural toxins that block motor activity, peripheral and then central nicotinic receptors were isolated and characterized. The electrical organs from the aquatic species of *Electrophorus* and, especially, *Torpedo* provide rich sources of nicotinic receptor. The electrical organ is derived embryologically from myoid tissue; however, in contrast to skeletal muscle, up to 40% of the surface of the membrane is excitable and contains cholinergic receptors. In vertebrate skeletal muscle, motor end plates occupy 0.1% or less of the cell surface. The discovery of seemingly irreversible antagonism of neuromuscular transmission by a toxins from venoms of the krait, *Bungarus multicinctus*, or varieties of the cobra, *Naja naja*, offered suitable markers for identification of the receptor. The toxins are peptides of about 7000 daltons. Radioisotope-labeled toxins were used by Changeux and his colleagues in 1970 to assay the isolated cholinergic receptor *in vitro*[22]. The toxins have extremely high affinities and slow rates of dissociation from the receptor, yet the interaction is noncovalent. *In situ* and *in vitro*, their behavior resembles that expected for a high-affinity antagonist. Since cholinergic neurotransmission mediates motor activity in marine vertebrates and mammals, a large number of peptide, terpinoid, and alkaloid toxins that block the nicotinic receptors have evolved to enhance predation or protect plant and animal species from predation[23]. Purification of the receptor from *Torpedo* ultimately led to isolation of complementary DNAs (cDNAs) that encode each of the subunits. These cDNAs, in turn, permitted the cloning of genes encoding the multiple receptor subunits from mammalian neurons and muscle[24].

4.3. Nicotinic receptor structure

The nicotinic receptor of the electrical organ and vertebrate skeletal muscle is a pentamer composed of four distinct subunits (a, b, g and d) in the stoichiometric ratio of 2:1:1:1, respectively. In mature, innervated muscle end plates, the g subunit is replaced by e, a closely related subunit. The individual subunits are about 40% identical in their amino acid sequences, arising from a common primordial gene. The nicotinic receptor became the prototype for other pentameric ligand-gated ion channels, which included the receptors for the inhibitory amino acids (g-aminobutyric acid and glycine) and certain serotonin ($5\text{-}HT_3$) receptors. Each of the subunits in the pentameric receptor has a molecular mass of 40000 to 60000 daltons. The amino-terminal 210 residues constitute virtually all the extracellular domain. This is followed by four transmembrane-spanning (TM) domains; the region between the third and fourth domains forms most of the cytoplasmic component. Each of the subunits within the nicotinic ACh receptor has an extracellular and an intracellular exposure on the postsynaptic membrane. The five subunits are arranged around a pseudo-axis of symmetry to circumscribe an internally located channel[25,26].

The receptor is an asymmetrical molecule (14 nm×8 nm) of 250000 daltons, with the bulk of the non-membrane-spanning domain on the extracellular surface. In junctional areas (*i.e.*, the motor end plate in skeletal muscle and the ventral surface of the electrical organ), the receptor is present at high densities (10000/mm^2) in a regular packing

order. This ordering of the receptors has allowed electron microscopic image reconstruction of its molecular structure. An ACh-binding protein homologous to only the extracellular domain of the nicotinic receptor has been identified in fresh- and saltwater snails and characterized structurally and pharmacologically[27].

This protein assembles as a homomeric pentamer and binds nicotinic receptor ligands with the expected selectivity; its crystal structure reveals an atomic organization expected of the nicotinic receptor. Moreover, fusion of the ACh-binding protein and the transmembrane spans of the receptor yield a functional protein that exhibits the channel gating and changes in state expected of the receptor[28]. This binding protein serves as both a structural and functional surrogate of the receptor and has provided a detailed understanding of the determinants governing ligand specificity of the nicotinic receptor. The agonist-binding sites are found at the subunit interfaces, but in muscle, only two of the five subunit interfaces, a g and a d, have evolved to bind ligands. The binding of agonists, reversible competitive antagonists, and the elapid a toxin is mutually exclusive and involves overlapping surfaces on the receptor. Both subunits forming the subunit interface contribute to ligand specificity. Measurements of membrane conductances demonstrate that rates of ion translocation are sufficiently rapid (5×10^7 ions per second) to require ion translocation through an open channel rather than by a rotating carrier of ions. Moreover, agonist-mediated changes in ion permeability (typically an inward movement of primarily Na^+ and secondarily Ca^{2+}) occur through a cation channel intrinsic to the receptor structure. The second transmembrane-spanning region on each of the five subunits forms the internal perimeter of the channel. The agonist-binding site is intimately coupled with an ion channel; in the muscle receptor, simultaneous binding of two agonist molecules results in a rapid conformational change that opens the channel. Both the binding and gating response show positive cooperativity. Details on the kinetics of channel opening have evolved from electrophysiological patch-clamp techniques that distinguish the individual opening and closing events of a single receptor molecule[29] and confirms that nicotinic acetylcholine receptors (nAChR) are pentameric ligandgated ion channels which is composed of subunits that consist of an extracellular domain that carries the ligand-binding site and a distinct ion-pore domain. Signal transduction results from the allosteric coupling between the two domains these are distance from the binding site to the gate of the pore domain is 50 Å[30]. However, receptor binding studies are specific for nicotinic cholinergic receptors which have been carried out on isolated vestibular epithelia of the frogs *Rana catesbiana* and *Rana temporaria*. Evidence is presented for the presence of nicotinic-like cholinergic receptors specifically associated with the sensory areas[31], and studied binding of atypical nicotinic agonist conformations conferring subtype selectivity and concludes that the nAChR has a crucial role in excitatory neurotransmission and plays an important target for drugs and insecticides. Diverse nAChR subtypes with various subunit combinations conferring differential selectivity for nicotinic drugs[32], and also identified family of genes coding for proteins homologous to α subunit of the muscle nicotinic acetylcholine receptor in the rat genome. These genes are transcribed in the central and peripheral nervous systems in areas which are known to contain functional nicotinic receptors[33]. The role played by β2-containing neuronal nicotinic receptors (nAChRs) in mediating nicotine′s side effects in the fetus and newborn. Pregnant WT and mutant mice lacking the β2 nAChR subunit were implanted with osmotic minipumps which delivered either water or a controlled dose of nicotine. Subsequently, there was a comparesion of the development of the sympathoadrenal system and breathing and arousal reflexes of offspring shortly after birth, a period of increased vulnerability to nicotine exposure[34]. On the other hand, neonicotinoids, like imidacloprid, are nAChR agonists with potent insecticidal activity. Since its introduction in the early 1990s, imidacloprid has become one of the most extensively used insecticides for both crop protection and animal health applications, the molecular basis of imidacloprid resistance, five nAChR subunits (Nlα1-Nlα4 and Nlβ1) have been cloned from *Nilaparvata lugens*. A comparison of nAChR subunit genes from imidacloprid-sensitive and imidacloprid-resistant populations has identified a single point mutation at a conserved position (Y151S) in two nAChR subunits, Nlα1 and Nlα3. A strong correlation between the frequency of the Y151S point mutation and the level of resistance to imidacloprid has been demonstrated by allele-specific PCR. By expression of hybrid nAChRs containing *Nilaparvata lugens* α and rat β2 subunits, evidence was obtained that demonstrates that mutation Y151S is responsible for a substantial reduction in specific [^{3}H] imidacloprid binding. This study provides direct evidence for the occurrence of target-site resistance to a neonicotinoid insecticide[35], and investigated about the nature of cation-π binding site in the nicotinic receptor and finds that the nicotinic acetylcholine receptor is the prototype ligand-gated ion channel. A number of aromatic amino acids have been identified as contributing to the agonist binding site, suggesting that cation-π interactions may be involved in binding the quaternary ammonium group of the agonist, acetylcholine[36]. The conformation of cholinergic molecules at nicotinic nerve receptors, and finds a correlation of the crystal structure analyses of the potent nicotinic agonists acetylcholine, acetyl-α-methylcholine, lactoylcholine, 1,1-dimethyl-4-phenylpiperazine, and nicotine allows one to determine the conformation of cholinergic agonists relevant to nicotinic nerve receptors[37]. The expression of neurotransmitter receptors encoded by mRNAs isolated from three human glioma cell lines. Oocytes injected with mRNAs from two glioblastoma cell lines did not show electrical responses to

the various neurotransmitters tested[38].

Modulation of nAChR by strychnine finds that strychnine is a potent and selective antagonist at glycine receptors which was found to inhibit muscle (α 1β 1γ δ, α 1β 1γ, and α 1β 1δ) and neuronal (α 2β 2 and α 2β 4) nicotinic acetylcholine receptors (AcChoRs) expressed in *Xenopus* oocytes. Strychnine alone (up to 500 μmol/L) did not elicit membrane currents in oocytes expressing AcChoRs, but when it was applied before, concomitantly, or during superfusion of acetylcholine (AcCho), it rapidly and reversibly inhibited the current elicited by AcCho (AcCho-current)[39]. Translation of exogenous messenger RNA coding for nAChRs produces functional receptors in *Xenopus* oocytes, in this study messenger RNA extracted from the electric organ of *Torpedo* was injected into *Xenopus* oocytes. This led to the synthesis and incorporation of functional acetylcholine receptors into the membrane of the oocyte. When activated by acetylcholine, these *Torpedo* acetylcholine receptors in the oocyte membrane opened channels whose ionic permeability resembled that of nicotinic receptors in other cells[40].

The localization of acetylcholine receptors (AChR) in the surface of developing myogenic cells of the chick embryo anterior and posterior latissimus dorsi muscles in relation to the process of innervation has been studied at the ultrastructural level utilizing a horseradish peroxidase-α-bungarotoxin conjugate. Localized concentrations of AChR were found in small regions 0.1-0.4 μm in width on the surface of myogenic cells of 10 to 14-day-old muscles[41], and also studied effects of acetylcholine and agents that mimic or block its physiological actions have been studied upon concentrations of guanosine 3′:5′-cyclic monophosphate (cyclic GMP) and adenosine 3′:5′-cyclic monophosphate (cyclic AMP) in slices of mammalian cerebral cortex, heart ventricle, and ileum. Acetylcholine, and cholinomimetic agents with a predominantly muscarinic action, such as methacholine, bethanechol, and pilocarpine, induced and increase in the concentration of cyclic GMP or a slight decrease in the concentration of cyclic AMP, in all three tissues studied[42].

The functional properties and cellular localization of the human neuronal α7 AcCho receptor (α7 AcChoR) and its L248T mutated (mut) form were investigated by expressing them alone or as gene fusions with the enhanced version of the green fluorescent protein (GFP). *Xenopus* oocytes injected with wild-type, mutα7, or the chimeric subunit cDNAs expressed receptors that gated membrane currents when exposed to AcCho. As already known, AcCho currents generated by wtα7 receptors decay much faster than those elicited by the mutα7 receptors[43]. Interplay of β2 nicotinic receptors and dopamine pathways in the control of spontaneous locomotion, and finds the acetylcholine (ACh) is a known modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nAChRs. Yet, the subunit composition and specific location of nAChRs involved in DA-mediated locomotion remain to be established *in vivo*. Mice lacking the β2 subunit of nAChRs (β2KO) display striking hyperactivity in the open field, which suggests an imbalance in DA neurotransmission[44]. However, mutation within domain M_2 of the nicotinic receptor converts 5-Hydroxytryptamine from antagonist to agonist, the study was done on the effects of 5-hydroxytryptamine (5HT) on homomeric neuronal nicotinic receptors (nAcChoR) expressed in *Xenopus* oocytes after injection of cDNA encoding the wild-type chicken subunit. AcCho elicited large currents that were reduced by 5HT in a reversible and dose-dependent manner, with a half-inhibitory concentration and a Hill coefficient[45]. Although study of the cholinergic receptor of cytotoxic T lymphocytes and cholinergic agonists have the ability of sensitized lymphocytes to injure cells bearing the sensitizing alloantigens, the cholinergic receptor of the attacking lymphocyte population has been studied with pharmacological manipulation of an *in vitro* system that quantitates the injury mediated by sensitized attacking cells upon target cells[46].

5. Conclusion

A variety of recent developments have potential benefits in boosting the effects of researchers working on drugs targeting cholinergic receptors as primary site for disorders. A wide array of data helps to achieve future outcome. This article serves as both structural and functional source of information regarding cholinergic receptors and provides a detailed understanding of the determinants governing specificity of muscarinic and nicotinic receptor to researchers.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

The authors wish to thank the department of National Medical library, AIIMS, New Delhi, and Dr. Pratap Kumar sahu, SPS, SOA Univ., BBSR, India, and we are also grateful to Chhattisgarh Council of Science & Technology (CGCOST) for providing grant to Mr. Anish Chandy (146/CCOST/2008) to make this work a success.

Comments

Background

Cholinergic system is an important system and a budding branch of autonomic nervous system which plays a vital role in memory, digestion, control of heart beat, blood

pressure, movement and many other functions. This article helps to give overall information about fundamentals of the cholinergic system, its receptors and ongoing research in this novel field.

Research frontiers

ANS innervation is divided into SNS and PSNS. The sympathetic division has thoracolumbar outflow, meaning that the neurons begin at the thoracic and lumbar (T1-L2) portions of the spinal cord.

Related reports

The present article's motto is to design and study two types of receptor, *i.e.* muscarinic receptors, which are found at parasympathetic target organs and at certain sympathetic targets – the eccrine sweat glands (which produces copious secretion in thermoregulation to release heat), and blood vessels in skeletal muscles (which are dilated), and nAchR, which mediates neurotransmission postsynaptically at the neuromuscular junction and peripheral autonomic ganglia; in the CNS, it largely controls release of neurotransmitters from presynaptic sites.

Innovations & breakthroughs

The present work enlightens cholinergic system which refers to those receptors which respond to the transmitter acetylcholine and are mostly parasympathetic. There are two types of cholinergic receptors, classified according to which, either they are stimulated by drug nicotine or by drug muscarine.

Applications

The basic applicability of present work is to approach for the cloning of the cDNAs that encode muscarinic receptors which are identified by five distinct gene products now designated as M_1, M_2... M_5. The nicotinic receptor of the electrical organ and vertebrate skeletal muscle is a pentamer composed of four distinct subunits (a, b, g and d) in the stoichiometric ratio of 2:1:1:1, respectively.

Peer review

This article serves as both structural and functional source of information regarding cholinergic receptors and provides a detailed understanding of the determinants governing specificity of muscarinic and nicotinic receptor to researchers.

References

[1] Ikehara O, Hayashi H, Waguri T, Kaji I, Karaki S, Kuwahara A, et al. Subepithelial trypsin induces enteric nerve-mediated anion secretion by activating proteinase-activated receptor 1 in the mouse cecum. *J Physiol Sci* 2012; **62**(3): 211-219.

[2] Kwon HJ, Kim HY. A pharmacologic pupillary test in the diagnosis of diabetic autonomic neuropathy. *Korean J Ophthalmol* 2009; **23**(4): 291-295.

[3] McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ, et al. Upregulation of CB (1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. *Behav Brain Res* 2013; **237**: 333-337.

[4] Jaakola VP, Vainio M, Sen S, Rehn M, Heimo H, Scheinin M, et al. Intracellularly truncated human alpha2B-adrenoceptors: stable and functional GPCRs for structural studies. *J Recept Signal Transduct Res* 2005; **25**(2): 99-124.

[5] Inoue R, Aosaki T, Miura M. Protein kinase C activity alters the effect of μ-opioid receptors on inhibitory postsynaptic current in the striosomes. *Neuroreport* 2012; **23**(3): 184-188.

[6] Rondinelli S, Näreoja K, Näsman J. Molecular conversion of muscarinic acetylcholine receptor M(5) to muscarinic toxin 7 (MT7)-binding protein. *Toxins (Basel)* 2011; **3**(11): 1393-1404.

[7] Mao X, Debenedittis P, Sun Y, Chen J, Yuan K, Jiao K, et al. Vascular smooth muscle cell *Smad4* gene is important for mouse vascular development. *Arterioscler Thromb Vasc Biol* 2012; **32**(9): 2171-2177.

[8] Kúdelová M, Halásová Z, Belvončíková P, Pančík P, Režuchová I, Valovičová M. Partial genome analysis of murine gammaherpesvirus 4556. *Acta Virol* 2012; **56**(3): 177-186.

[9] Zhu Z, Bowman HR, Baghdoyan HA, Lydic R. Morphine increases acetylcholine release in the trigeminal nuclear complex. *Sleep* 2008; **31**(12): 1629-1637.

[10] Azam L, McIntosh JM. Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [^{3}H] norepinephrine release from mouse hippocampal synaptosomes. *Mol Pharmacol* 2006; **70**(3): 967-976.

[11] Miyoshi K, Kawakami N, Wakayama Y, Izumi N, Horio S, Fukui H. Histamine H1 receptor down-regulation mediated by M_3 muscarinic acetylcholine receptor subtype. *J Pharmacol Sci* 2004; **95**(4): 426-434.

[12] Silva DC, de Medeiros WA, Batista Ide F, Pimenta DC, Lebrun I, Abdalla FM, et al. Characterization of a new muscarinic toxin from the venom of the Brazilian coral snake *Micrurus lemniscatus* in rat hippocampus. *Life Sci* 2011; **89**(25-26): 931-938.

[13] Dasari S, Gulledge AT. M_1 and M_4 receptors modulate hippocampal pyramidal neurons. *J Neurophysiol* 2011; **105**(2): 779-792.

[14] Freschi JE. The effect of subtype-selective muscarinic receptor antagonists on the cholinergic current in motoneurons of the lobster cardiac ganglion. *Brain Res* 1991; **552**(1): 87-92.

[15] Tian MK, Bailey CD, De Biasi M, Picciotto MR, Lambe EK. Plasticity of prefrontal attention circuitry: upregulated muscarinic excitability in response to decreased nicotinic signaling following deletion of α5 or β2 subunits. *J Neurosci* 2011; **31**(45): 16458-16463.

[16] Guo J, Schofield GG. Activation of muscarinic m5 receptors inhibits recombinant KCNQ2/KCNQ3 K^+ channels expressed in HEK293T cells. *Eur J Pharmacol* 2003; **462**(1-3): 25-32.

[17] Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M_3 receptor. *Br J Pharmacol* 2006; **148**(7): 927-937.

[18] Yamanishi T, Chapple CR, Yasuda K, Williams RC. The role of

M_2 muscarinicreceptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M_3 inactivation. *J Urol* 2002; **167**(1): 397-401.

[19] Suga H, Sawyer GW, Ehlert FJ. Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M_1 and M_2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343. *Mol Pharmacol* 2010; **78**(4): 745-755.

[20] Kimber MJ, Sayegh L, El-Shehabi F, Song C, Zamanian M, Woods DJ, et al. Identification of an *Ascaris* G protein-coupled acetylcholine receptor with atypical muscarinic pharmacology. *Int J Parasitol* 2009; **39**(11): 1215-1222.

[21] Li S, Cullen WK, Anwyl R, Rowan MJ. Muscarinic acetylcholine receptor-dependent induction of persistent synaptic enhancement in rat hippocampus *in vivo*. *Neuroscience* 2007; **144**(2): 754-761.

[22] Marcon F, Leblanc M, Vetter I, Lewis RJ, Escoubas P, Nicholson GM. Pharmacological characterization of α-elapitoxin-Al2a from the venom of the Australian pygmy copperhead (*Austrelaps labialis*): an atypical long-chain α-neurotoxin with only weak affinity for α7 nicotinic receptors. *Biochem Pharmacol* 2012; **84**(6): 851-863.

[23] Taylor P, Talley TT, Radic Z, Hansen SB, Hibbs RE, Shi J. Structure-guided drug design: conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes. *Biochem Pharmacol* 2007; **74**: 1164-1171.

[24] Labriola JM, daCosta CJ, Wang S, Figeys D, Smith JC, Sturgeon RM, et al. Phospholipase C activity affinity purifies with the torpedo nicotinic acetylcholine receptor. *J Biol Chem* 2010; **285**(14): 10337-10343.

[25] Liu Y, Sugiura Y, Padgett D, Lin W. Postsynaptic development of the neuromuscular junction in mice lacking the gamma-subunit of muscle nicotinic acetylcholine receptor. *J Mol Neurosci* 2010; **40**(1-2): 21-26.

[26] Oikawa H, Nakamichi N, Kambe Y, Ogura M, Yoneda Y. An increase in intracellular free calcium ions by nicotinic acetylcholine receptors in a single cultured rat cortical astrocyte. *J Neurosci Res* 2005; **79**(4): 535-544.

[27] Surdacki A, Marewicz E, Wieczorek-Surdacka E, Rakowski T, Szastak G, Pryjma J, et al. Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina. *Nephrol Dial Transplant* 2010; **25**(8): 2576-2583.

[28] Fujita K, Teramura N, Hattori S, Irie S, Mitsunaga-Nakatsubo K, Akimoto Y, et al. Mammalian arylsulfatase A functions as a novel component of the extracellular matrix. *Connect Tissue Res* 2010; **51**(5): 388-396.

[29] Goreshnik I, Maly DJ. A small molecule-regulated guanine nucleotide exchange factor. *J Am Chem Soc* 2010; **132**(3): 938-940.

[30] Taly A, Corringer PJ, Grutter T, Carvalho LP, Karplus M, Changeux JP. Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors. *Proc Natl Acad Sci U S A* 2006; **103**(45): 16965-16970.

[31] Puskar NL, Lester HA, Dougherty DA. Probing the effects of residues located outside the agonist binding site on drug-receptor selectivity in the nicotinic receptor. *ACS Chem Biol* 2012; **7**(5): 841-846.

[32] Tomizawa M, Maltby D, Talley TT, Durkin KA, Medzihradszky KF, Burlingame AL, et al. Casida, atypical nicotinic agonist bound conformations conferring subtype selectivity. *Proc Natl Acad Sci U S A* 2008; **105**(5): 1728-1732.

[33] Kaczmarczyk A, Bowra S, Elek Z, Vincze E. Quantitative RT-PCR based platform for rapid quantification of the transcripts of highly homologous multigene families and their members during grain development. *BMC Plant Biol* 2012; **12**(1): 184.

[34] Cohen G, Roux JC, Grailhe R, Malcolm G, Changeux JP, Lagercrantz H. Perinatal exposure to nicotine causes deficits associated with a loss of nicotinic receptor function. *Proc Natl Acad Sci U S A* 2005; **102**(10): 3817-3821.

[35] Liu Z, Williamson MS, Lansdell SJ, Denholm I, Han Z, Millar NS, et al. A nicotinic acetylcholine receptor mutation conferring target-site resistance to imidacloprid in *Nilaparvata lugens* (brown planthopper). *Proc Natl Acad Sci U S A* 2005; **102**(24): 8420-8425.

[36] Lummis SC, L Beene D, Harrison NJ, Lester HA, Dougherty DA. A cation-pi binding interaction with a tyrosine in the binding site of the GABAC receptor. *Chem Biol* 2005; **12**(9): 993-997.

[37] Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. *Physiol Rev* 2012; **92**(3): 1189-1234.

[38] Xu J, Xu M, Rossi GC, Pasternak GW, Pan YX. Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1. *Mol Pain* 2011; **7**(1): 9.

[39] Adermark L. Modulation of endocannabinoid-mediated long-lasting disinhibition of striatal output by cholinergic interneurons. *Neuropharmacology* 2011; **61**(8): 1314-1320.

[40] Kobayashi S, Iio H, Aoshima H. New translation system of mRNA coding for neurotransmitter receptors using oocytes of the newt, *Cynops pyrrhogaster*. *Brain Res* 1986; **387**(1): 93-96.

[41] Makhnovskiy DA, Murzina GB, Pivovarov AS. Cholinergic receptor exocytosis under conditions of depression of acetylcholine-induced current in edible snail neurons in cellular analogue of habituation. *Bull Exp Biol Med* 2012; **153**(4): 424-427.

[42] Yoto A, Motoki M, Murao S, Yokogoshi H. Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. *J Physiol Anthropol* 2012; **31**: 28.

[43] Palma E, Mileo AM, Martinez-Torres A, Eusebi F, Miledi R. Some properties of human neuronal alpha 7 nicotinic acetylcholine receptors fused to the green fluorescent protein. *Proc Natl Acad Sci U S A* 2002; **99**(6): 3950-3955.

[44] Avale ME, Faure P, Pons S, Robledo P, Deltheil T, David DJ, et al. Interplay of beta2 nicotinic receptors and dopamine pathways in the control of spontaneous locomotion. *Proc Natl Acad Sci U S A* 2008; **105**(41): 15991-15996.

[45] Lee WY, Free CR, Sine SM. Nicotinic receptor interloop proline anchors beta1-beta2 and Cys loops in coupling agonist binding to channel gating. *J Gen Physiol* 2008; **132**(2): 265-278.

[46] Charoenying T, Suriyo T, Thiantanawat A, Chaiyaroj SC, Parkpian P, Satayavivad J. Effects of paraoxon on neuronal and lymphocytic cholinergic systems. *Environ Toxicol Pharmacol* 2011; **31**(1): 119-128.